Clinical Trials Logo

Filter by:
NCT ID: NCT05597046 Completed - Clinical trials for Total Knee Replacement

Qualitative Interviews With Healthcare Professionals

Start date: November 3, 2022
Phase:
Study type: Observational

PLANNING PHASE- Qualitative interviews with Healthcare Professionals to assist in the development of a new Patient Reported Outcome Measure (PROM) to assess patient's emotional wellbeing, and perceptions of Total Knee Replacement (TKR) surgery for the treatment of knee arthritis.

NCT ID: NCT05597020 Completed - Nocturia Clinical Trials

A Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia

Start date: January 18, 2023
Phase: Phase 4
Study type: Interventional

A post approval study to investigate the efficacy of daridorexant in subjects with insomnia and comorbid nocturia

NCT ID: NCT05596734 Completed - COVID-19 Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

Start date: October 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). Participants will receive either: - qIRV (22/23)/bivalent BNT162b2 (original/Omi BA.4/BA.5), at 1 of the 3 dose-level combinations - qIRV (22/23) at dose level 1, - qIRV (22/23) at dose level 2, or - bivalent BNT162b2 (original/Omi BA.4/BA.5) at dose level 1 administered concurrently in the opposite arm to commercially licensed quadrivalent influenza vaccine (QIV). Substudy B: This Phase 1/2 study will describe the safety, tolerability, and immunogenicity of quadrivalent influenza vaccine (qIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), trivalent influenza vaccine (tIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), and bivalent influenza vaccine (bIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5) when given concurrently with licensed quadrivalent influenza vaccine (QIV).

NCT ID: NCT05596500 Completed - Clinical trials for Inflammatory Response

Blueberry-protein Supplementation and Exercise

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

This study is the human clinical trial component of an SBIR grant with Sinnovatek (funded). Cyclists (n=20) will consume a blueberry-protein, blueberry, or placebo supplement for 2 weeks prior to cycling for 2.5 h at high intensity. Washout periods (2 weeks) will separate the 3 trials, and the cyclists will crossover (randomized) to one of the two others supplements for 2 weeks, and then engage in additional 2.5 h cycling bouts. Blood and urine samples will be collected pre- and post-supplementation for each of the 3 trials. Blood samples will also be collected immediately after and 1.5h- and 24h-post-exercise. Blood samples will be analyzed for inflammation and oxidative stress outcomes. Urine samples will be analyzed for blueberry gut-derived phenolics.

NCT ID: NCT05595980 Completed - Clinical trials for Gastrointestinal Health

The Effects of a Novel Probiotic on Gastrointestinal Health in Generally Healthy Adults

Start date: September 19, 2022
Phase: N/A
Study type: Interventional

The primary objective of this study is to investigate the effect of an oral probiotic (Bacillus sp. spore preparation) on abdominal bloating, flatulence, and burping in generally healthy adults. Secondary outcomes include intestinal barrier integrity and fecal microbiome properties (taxonomical structure, diversity, and function).

NCT ID: NCT05595629 Completed - Preeclampsia Clinical Trials

App-based Remote Blood Pressure Monitoring

Start date: November 7, 2022
Phase: N/A
Study type: Interventional

Remote postpartum blood pressure monitoring program with text messages has been shown to increase adherence to recommended postpartum blood pressure checks among those with hypertension at discharge from birth hospitalization, but these programs require medically trained professionals to respond to each individual text message. A bluetooth-enabled blood pressure cuff that synchs automatically a smartphone application that leverages Artificial Intelligence to provide tailored recommendations based on recorded blood pressure measurements--and can also provide on-demand education on hypertension--may be less costly way to provide similar support.

NCT ID: NCT05595382 Completed - Healthy Clinical Trials

Motivations to Transplant Registry Participation

Start date: October 10, 2022
Phase: N/A
Study type: Interventional

The current study seeks to understand factors that influence college students' likelihood of participating the National Marrow Donor Program (NMDP)/Be the Match for bone marrow and stem cell donations. The secondary aim is to compare emotional and rational approaches to encouraging participation in the registry and how these approaches may impact intentions to participate in the NMDP.

NCT ID: NCT05594745 Completed - Dry Eye Syndromes Clinical Trials

Treatment Regimens in Meibomian Gland Dysfunction

Start date: March 2, 2021
Phase: Phase 4
Study type: Interventional

This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.

NCT ID: NCT05594615 Completed - COVID-19 Clinical Trials

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Start date: October 6, 2022
Phase: Phase 1
Study type: Interventional

A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.

NCT ID: NCT05594602 Completed - COVID-19 Clinical Trials

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Start date: October 6, 2022
Phase: Phase 1
Study type: Interventional

A Drug-Drug Interaction study to assess the effects of itraconazole, carbamazepine and quinidine on the Pharmacokinetics and Safety of EDP-235.